Apolipoprotein C-III is Linked to the Insulin Resistance and Beta-cell Dysfunction That Are Present in Rheumatoid Arthritis

Overview

Journal Arthritis Res Ther

Publisher Biomed Central

Specialty Rheumatology

Date 2022 May 31

PMID 35637531

Authors

Candelaria Martin-Gonzalez

Tomas Martin-Folgueras

Juan Carlos Quevedo-Abeledo

Antonia de Vera-Gonzalez

Alejandra Gonzalez-Delgado

Laura de Armas-Rillo

Miguel A Gonzalez-Gay

Ivan Ferraz-Amaro

Affiliations

Soon will be listed here.

Abstract

Background: Insulin resistance and beta-cell dysfunction are manifestations of rheumatoid arthritis (RA). Apolipoprotein C-III (ApoC3) has been associated with such insulin resistance and beta-cell dysfunction in the general population. Our purpose was to study whether ApoC3 is also related to the insulin resistance and beta-cell dysfunction that are present in patients with RA.

Methods: Three hundred thirty-eight non-diabetic patients with RA who had a glycemia lower than 110 mg/dl were recruited. Insulin, C-peptide, and ApoC3 were assessed. Insulin resistance and beta-cell function were calculated using the Homeostasis Model Assessment (HOMA2) indices. A multivariable regression analysis was performed to study the relationship of ApoC3 with those molecules and indices adjusting for classic factors associated with insulin resistance that included glucocorticoids.

Results: ApoC3 was related to significant higher levels of circulating insulin (beta coef. 0.37 [95%CI 0.01-0.73] µU/ml, p = 0.044) and C-peptide (beta coef. 0.13 [95%CI 0.05-0.22] ng/ml, p = 0.003), and higher insulin resistance -HOMA2-IR- (beta coef. 0.05 [95%CI 0.00-0.09], p = 0.041) and beta-cell dysfunction -HOMA2-%B- (beta coef. 2.94 [95%CI 0.07-5.80], p = 0.044) indices. This was found after a fully multivariable analysis that included, among others, prednisone intake and the classic factors associated with carbohydrate metabolism such as triglycerides, waist circumference, and obesity.

Conclusion: ApoC3, insulin resistance, and beta-cell dysfunction are independently associated in patients RA.

Citing Articles

Targeting Apolipoprotein C-III for the Management of Severe Hypertriglyceridemia: Current Research and Future Directions.

Shah M, Sharma A, Ayyad M, Swartz E, Jafrani D, Gala D Cureus. 2024; 16(8):e67091.

PMID: 39286687 PMC: 11405074. DOI: 10.7759/cureus.67091.

Association of Urine (pH < 5.5) with Community Periodontal Index (CPI) and the Number of Remaining Teeth in Korean Adults: A Cross-Sectional Study Using Data from Korea National Health and Nutrition Examination Survey 2016-2018.

Hwang S, Park J Healthcare (Basel). 2024; 12(7).

PMID: 38610162 PMC: 11011296. DOI: 10.3390/healthcare12070740.

Potential association of genetically predicted lipid and lipid-modifying drugs with rheumatoid arthritis: A Mendelian randomization study.

Huang Z, Cui T, Yao J, Wu Y, Zhu J, Yang X PLoS One. 2024; 19(2):e0298629.

PMID: 38416767 PMC: 10901327. DOI: 10.1371/journal.pone.0298629.

A Peripheral Blood Signature of Increased Th1 and Myeloid Cells Combined with Serum Inflammatory Mediators Is Associated with Response to Abatacept in Rheumatoid Arthritis Patients.

Goutakoli P, Papadaki G, Repa A, Avgoustidis N, Kalogiannaki E, Flouri I Cells. 2023; 12(24).

PMID: 38132128 PMC: 10741898. DOI: 10.3390/cells12242808.

Apolipoprotein C3: form begets function.

Bornfeldt K J Lipid Res. 2023; 65(1):100475.

PMID: 37972731 PMC: 10805671. DOI: 10.1016/j.jlr.2023.100475.

References

Christopoulou E, Tsimihodimos V, Filippatos T, Elisaf M . Apolipoprotein CIII and diabetes. Is there a link?. Diabetes Metab Res Rev. 2018; 35(3):e3118. DOI: 10.1002/dmrr.3118. View

Kremer J, Genovese M, Keystone E, Taylor P, Zuckerman S, Ruotolo G . Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis. Arthritis Rheumatol. 2016; 69(5):943-952. DOI: 10.1002/art.40036. View

Taskinen M, Boren J . Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?. Curr Atheroscler Rep. 2016; 18(10):59. PMC: 5018018. DOI: 10.1007/s11883-016-0614-1. View

Aletaha D, Smolen J . The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005; 23(5 Suppl 39):S100-8. View

Ingelsson E, Sullivan L, Murabito J, Fox C, Benjamin E, Polak J . Prevalence and prognostic impact of subclinical cardiovascular disease in individuals with the metabolic syndrome and diabetes. Diabetes. 2007; 56(6):1718-26. DOI: 10.2337/db07-0078. View

Ferraz-Amaro I, Gonzalez-Gay M, Diaz-Gonzalez F . Retinol-binding protein 4 in rheumatoid arthritis-related insulin resistance and β-cell function. J Rheumatol. 2014; 41(4):658-65. DOI: 10.3899/jrheum.130834. View

Ma M, Liu H, Yu J, He S, Li P, Ma C . Triglyceride is independently correlated with insulin resistance and islet beta cell function: a study in population with different glucose and lipid metabolism states. Lipids Health Dis. 2020; 19(1):121. PMC: 7268278. DOI: 10.1186/s12944-020-01303-w. View

Weir G, Bonner-Weir S . Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes. 2004; 53 Suppl 3:S16-21. DOI: 10.2337/diabetes.53.suppl_3.s16. View

Quevedo-Abeledo J, Sanchez-Perez H, Tejera-Segura B, de Armas-Rillo L, Ojeda S, Erausquin C . Higher Prevalence and Degree of Insulin Resistance in Patients With Rheumatoid Arthritis Than in Patients With Systemic Lupus Erythematosus. J Rheumatol. 2020; 48(3):339-347. DOI: 10.3899/jrheum.200435. View

10.

Aletaha D, Neogi T, Silman A, Funovits J, Felson D, Bingham 3rd C . 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62(9):2569-81. DOI: 10.1002/art.27584. View

11.

Smolen J, Breedveld F, Schiff M, Kalden J, Emery P, Eberl G . A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003; 42(2):244-57. DOI: 10.1093/rheumatology/keg072. View

12.

Tejera-Segura B, Lopez-Mejias R, de Vera-Gonzalez A, Jimenez-Sosa A, Olmos J, Hernandez J . Relationship Between Insulin Sensitivity and β-Cell Secretion in Nondiabetic Subjects with Rheumatoid Arthritis. J Rheumatol. 2018; 46(3):229-236. DOI: 10.3899/jrheum.180198. View

13.

Blaschke S, Rinke K, Maring M, Flad T, Patschan S, Jahn O . Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis. Arthritis Res Ther. 2015; 17:45. PMC: 4383078. DOI: 10.1186/s13075-015-0553-1. View

14.

Cerf M . Beta cell dysfunction and insulin resistance. Front Endocrinol (Lausanne). 2013; 4:37. PMC: 3608918. DOI: 10.3389/fendo.2013.00037. View

15.

Avall K, Ali Y, Leibiger I, Leibiger B, Moede T, Paschen M . Apolipoprotein CIII links islet insulin resistance to β-cell failure in diabetes. Proc Natl Acad Sci U S A. 2015; 112(20):E2611-9. PMC: 4443338. DOI: 10.1073/pnas.1423849112. View

16.

Tejera-Segura B, Lopez-Mejias R, de Vera-Gonzalez A, Delgado-Gonzalez A, Gonzalez-Gay M, Ferraz-Amaro I . Implication of CXCL5 (epithelial neutrophil-activating peptide 78) in the development of insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2018; 37(3):373-379. View

17.

Knowlton N, Wages J, Centola M, Giles J, Bathon J, Quiroga C . Apolipoprotein B-containing lipoprotein subclasses as risk factors for cardiovascular disease in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012; 64(7):993-1000. PMC: 3552355. DOI: 10.1002/acr.21646. View

18.

Zewinger S, Reiser J, Jankowski V, Alansary D, Hahm E, Triem S . Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. Nat Immunol. 2019; 21(1):30-41. DOI: 10.1038/s41590-019-0548-1. View

19.

Ferraz-Amaro I, Lopez-Mejias R, Tejera-Segura B, de Vera-Gonzalez A, Ubilla B, Olmos J . Amylin in the insulin resistance of patients with rheumatoid arthritis. Clin Exp Rheumatol. 2018; 36(3):421-427. View

20.

Ashcroft F, Rorsman P . Diabetes mellitus and the β cell: the last ten years. Cell. 2012; 148(6):1160-71. PMC: 5890906. DOI: 10.1016/j.cell.2012.02.010. View